Tech Alert: Transition reminder – Vitamin B6 – maximum dose and warnings; Artemisinin containing ingredients – pregnancy warning statement; Mollusc-derived ingredients – warning 

Members are reminded that the end of the transition period for existing products that contain Vitamin B6, certain Artemisinin containing ingredients and Mollusc-derived ingredients is 28 Feb 2023. Sponsors have been provided a 12-month transition period from 1 March 2022 to bring existing listed medicines into compliance. From 1 March 2023:

– The maximum recommended daily dose (MRDD) for products that contain vitamin B6 has been changed to 100 mg pyridoxine/day. Existing products that contain vitamin B6 must include a warning statement if the medicine contains more than 10 mg of pyridoxine per maximum recommended daily dose (MRDD).

– Existing products that contain certain Artemisinin containing ingredients must include a pregnancy warning statement.

– Existing products that contain Mollusc derived ingredients must include a new warning statement.

Please read today’s technical alert for more details

LinkedIn
Facebook
Twitter
Email

RECENT ARTICLES

Vale Stephen Myers

It is with great sadness that we learned of the passing of Emeritus Professor Stephen Myers late last week. Stephen was a giant in the

Read More